Electroporation therapy enters Phase II trials:
This article was originally published in Clinica
Executive Summary
The FDA has agreed to let US company Genetronics Biomedical begin Phase II clinical trials for electroporation therapy in advanced head and neck cancer patients in whom standard treatment has failed. Electroporation allows easier and more efficient delivery of pharmaceuticals or genes by using an electric field to open the pores in human cells.